Brain Cancer
FDA OKs Berubicin for GBM Treatment
December 22, 2020
Article
The FDA has approved an investigational new drug application for berubicin for the treatment of patients with glioblastoma multiforme.
AV-GBM-1 Vaccine Improves Glioblastoma Outcomes
November 18, 2020
Article
AV-GBM-1, a personalized cancer vaccine, demonstrated an improvement in progression-free survival (PFS) in patients with newly diagnosed glioblastoma, according to data from a phase 2 trial (NCT03400917).
FDA Grants Fast Track Status to Paxalisib for GBM Treatment
August 21, 2020
Article
The FDA has granted a fast track designation to paxalisib for the treatment of patients with glioblastoma.
FDA Grants Fast Track Status to Enzastaurin to Treat Newly Diagnosed GBM
July 23, 2020
Article
The FDA has granted a fast track designation for the PKCβ inhibitor enzastaurin for the treatment of patients with newly diagnosed glioblastoma.
FDA Accepts BLA for Bevacizumab Biosimilar
March 06, 2020
Article
The FDA has accepted a biologics license application for a proposed biosimilar for bevacizumab (Avastin), according to an announcement by Mylan during its fourth quarter 2019 earnings call.
Checkpoint Blockade Plus Vaccines Show Synergy in Early GBM Trials
December 06, 2019
Article
Glioblastoma is historically difficult to treat, but recent research shows some potential for immunotherapy/vaccine combinations for these patients.
New Agents Show Promise in Treating Patients with IDH1-Mutant Low-Grade Glioma
November 26, 2019
Article
Two new single agents led to brain penetrance and 2-hydroxyglutarate (2-HG) suppression in patients with low-grade glioma who harbor IDH1 mutations, according to updated findings.
FDA Approves Bevacizumab Biosimilar for 5 Cancer Types
June 28, 2019
Article
The Food and Drug Administration approved bevacizumab-bvzr (Zirabev) – a biosimilar for bevacizumab (Avastin) for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.
Quality of Life Is an Important Endpoint in Cancer Trials
June 22, 2019
Video
Health-related quality of life (QOL) is becoming an increasingly important endpoint in cancer clinical trials.
App for Tracking GBM Symptoms May Fuel Cancer Advancements
June 07, 2019
Article
Patients can track symptoms and anonymously send them to glioblastoma researchers around the world.